BioRender Template
Bispecific Antibody Design
Use This Template – Free
No credit card required to sign up.
This template is fully editable in BioRender
- Swap in different text, shapes, & icons
- Recolor and rearrange every icon, line, & label
- Export or share for any use case
Join 4M+ scientists already making publication-ready figures
Description:
This template was adapted from the original submission. Edits were made to enhance scientific accuracy, optimal usability and/or to meet industry-leading design standards for science communication.
(A) Illustrative representation of Blinatumomab, the only FDA approved bispecific antibody, designed to target CD3 (healthy T-cells) and CD19 (malignant hematologic tumors) through anti-CD3/CD19 single-chain variable fragments. (B) Mosunetuzumab, a bispecific antibody under clinical trial evaluation, is designed to target CD3 and CD20, where the CD20 targeting is achieved through the full-length domain of the antibody Fc domain.
Updated
August 2026
BioRender icons and templates meet journal, grant, and copyright standards. For AI-generated figures, policies vary. Learn More
Not quite the right template? Discover more.
Search thousands of templates across 30+ life-science fields.
Popular topics:
Cell
Cancer
Drug Delivery
Mechanism of Action
Pathway
Try a synonym, or sign up to suggest a template from the app.
Newest templates
BioRender Template FAQs
This template was adapted from the original submission. Edits were made to enhance scientific accuracy, optimal usability and/or to meet industry-leading design standards for science communication.
(A) Illustrative representation of Blinatumomab, the only FDA approved bispecific antibody, designed to target CD3 (healthy T-cells) and CD19 (malignant hematologic tumors) through anti-CD3/CD19 single-chain variable fragments. (B) Mosunetuzumab, a bispecific antibody under clinical trial evaluation, is designed to target CD3 and CD20, where the CD20 targeting is achieved through the full-length domain of the antibody Fc domain.